Braun Stacey Associates’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Braun Stacey Associates’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-164,775	Closed	-$16.8M	–	132
2023 Q2	$16.8M	Sell	164,775 -146,235	-47%	-$13.8M	0.78%	59
2023 Q1	$28.3M	Buy	+311,010	New	+$18.3M	0.74%	63

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Braun Stacey Associates's RETA Position: Q3 2023 in Review

Braun Stacey Associates sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 164,775 shares — an estimated $16.8M sold.

Braun Stacey Associates first reported a position in RETA in Q1 2023 and held it in 2 quarters. The position peaked at $28.3M in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Braun Stacey Associates reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Braun Stacey Associates sold 164,775 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $16.8M.
Braun Stacey Associates first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2023 and held it in 2 quarters.
Braun Stacey Associates's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $28.3M in Q1 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Braun Stacey Associates's 13F filing for Q3 2023, filed 21 Nov 2023.